Trial Profile
Vedolizumab Induction May Prevent Celiac Enteritis After Gluten Challenge in Established Celiac Patients in Histological Remission
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Coeliac disease
- Focus Therapeutic Use
- 08 Oct 2018 Status changed from recruiting to discontinued.
- 25 Jun 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 25 Jun 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2018.